Autoantibodies and Biomarker Discovery

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

There is growing evidence for the contribution of immune pathogenesis to many systemic diseases, including cancer, diabetes, and neurologic disorders. To understand the functional consequences of immune dysregulation, biomarkers are needed that detect subtle antigen-specific changes within the normal variation of immune responses. Recent advances in proteomic methodologies have resulted in accurate measurements of antigen-specific autoantibodies. These autoantibodies target self-antigens due to abnormalities in protein expression or structure that are associated with disease. Antibodies have been detected using diverse methods of antigen display, including phage display, multidimensional cell fractionation, protein arrays, and peptide and peptoid arrays. Next-generation sequencing of cDNA from disease tissue is providing an even broader source of potential autoantigens due to mutations and splice variation. In addition to their use for clinical diagnostics, the breadth and the specificity of the immune response provides insight into the role of immune regulation in the pathogenesis of these diseases.

Original languageEnglish (US)
Title of host publicationProteomic and Metabolomic Approaches to Biomarker Discovery
PublisherElsevier Inc.
Pages363-378
Number of pages16
ISBN (Print)9780123944467
DOIs
StatePublished - Jun 2013

Fingerprint

Biomarkers
Autoantibodies
Antigens
Peptoids
Display devices
Cell Fractionation
Protein Array Analysis
Bacteriophages
Autoantigens
Fractionation
Medical problems
Nervous System Diseases
Proteomics
Proteins
Complementary DNA
Tissue
Peptides
Mutation
Antibodies
Neoplasms

Keywords

  • Autoantibodies
  • Autoimmunity
  • Biomarker
  • Diabetes
  • Tumor antigen

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Qiu, J., & Anderson, K. (2013). Autoantibodies and Biomarker Discovery. In Proteomic and Metabolomic Approaches to Biomarker Discovery (pp. 363-378). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394446-7.00023-6

Autoantibodies and Biomarker Discovery. / Qiu, Ji; Anderson, Karen.

Proteomic and Metabolomic Approaches to Biomarker Discovery. Elsevier Inc., 2013. p. 363-378.

Research output: Chapter in Book/Report/Conference proceedingChapter

Qiu, J & Anderson, K 2013, Autoantibodies and Biomarker Discovery. in Proteomic and Metabolomic Approaches to Biomarker Discovery. Elsevier Inc., pp. 363-378. https://doi.org/10.1016/B978-0-12-394446-7.00023-6
Qiu J, Anderson K. Autoantibodies and Biomarker Discovery. In Proteomic and Metabolomic Approaches to Biomarker Discovery. Elsevier Inc. 2013. p. 363-378 https://doi.org/10.1016/B978-0-12-394446-7.00023-6
Qiu, Ji ; Anderson, Karen. / Autoantibodies and Biomarker Discovery. Proteomic and Metabolomic Approaches to Biomarker Discovery. Elsevier Inc., 2013. pp. 363-378
@inbook{8dd37698941147978aa4e35f69a14f78,
title = "Autoantibodies and Biomarker Discovery",
abstract = "There is growing evidence for the contribution of immune pathogenesis to many systemic diseases, including cancer, diabetes, and neurologic disorders. To understand the functional consequences of immune dysregulation, biomarkers are needed that detect subtle antigen-specific changes within the normal variation of immune responses. Recent advances in proteomic methodologies have resulted in accurate measurements of antigen-specific autoantibodies. These autoantibodies target self-antigens due to abnormalities in protein expression or structure that are associated with disease. Antibodies have been detected using diverse methods of antigen display, including phage display, multidimensional cell fractionation, protein arrays, and peptide and peptoid arrays. Next-generation sequencing of cDNA from disease tissue is providing an even broader source of potential autoantigens due to mutations and splice variation. In addition to their use for clinical diagnostics, the breadth and the specificity of the immune response provides insight into the role of immune regulation in the pathogenesis of these diseases.",
keywords = "Autoantibodies, Autoimmunity, Biomarker, Diabetes, Tumor antigen",
author = "Ji Qiu and Karen Anderson",
year = "2013",
month = "6",
doi = "10.1016/B978-0-12-394446-7.00023-6",
language = "English (US)",
isbn = "9780123944467",
pages = "363--378",
booktitle = "Proteomic and Metabolomic Approaches to Biomarker Discovery",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Autoantibodies and Biomarker Discovery

AU - Qiu, Ji

AU - Anderson, Karen

PY - 2013/6

Y1 - 2013/6

N2 - There is growing evidence for the contribution of immune pathogenesis to many systemic diseases, including cancer, diabetes, and neurologic disorders. To understand the functional consequences of immune dysregulation, biomarkers are needed that detect subtle antigen-specific changes within the normal variation of immune responses. Recent advances in proteomic methodologies have resulted in accurate measurements of antigen-specific autoantibodies. These autoantibodies target self-antigens due to abnormalities in protein expression or structure that are associated with disease. Antibodies have been detected using diverse methods of antigen display, including phage display, multidimensional cell fractionation, protein arrays, and peptide and peptoid arrays. Next-generation sequencing of cDNA from disease tissue is providing an even broader source of potential autoantigens due to mutations and splice variation. In addition to their use for clinical diagnostics, the breadth and the specificity of the immune response provides insight into the role of immune regulation in the pathogenesis of these diseases.

AB - There is growing evidence for the contribution of immune pathogenesis to many systemic diseases, including cancer, diabetes, and neurologic disorders. To understand the functional consequences of immune dysregulation, biomarkers are needed that detect subtle antigen-specific changes within the normal variation of immune responses. Recent advances in proteomic methodologies have resulted in accurate measurements of antigen-specific autoantibodies. These autoantibodies target self-antigens due to abnormalities in protein expression or structure that are associated with disease. Antibodies have been detected using diverse methods of antigen display, including phage display, multidimensional cell fractionation, protein arrays, and peptide and peptoid arrays. Next-generation sequencing of cDNA from disease tissue is providing an even broader source of potential autoantigens due to mutations and splice variation. In addition to their use for clinical diagnostics, the breadth and the specificity of the immune response provides insight into the role of immune regulation in the pathogenesis of these diseases.

KW - Autoantibodies

KW - Autoimmunity

KW - Biomarker

KW - Diabetes

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=84902040616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902040616&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-394446-7.00023-6

DO - 10.1016/B978-0-12-394446-7.00023-6

M3 - Chapter

SN - 9780123944467

SP - 363

EP - 378

BT - Proteomic and Metabolomic Approaches to Biomarker Discovery

PB - Elsevier Inc.

ER -